Status:
NOT_YET_RECRUITING
Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients
Lead Sponsor:
Tanta University
Conditions:
Diabetic Macular Edema (DME)
Retinal Vein Occlusion (RVO)
Eligibility:
All Genders
20-60 years
Phase:
EARLY_PHASE1
Brief Summary
Generally, DM is caused by insufficient insulin secretion in the body; however, the other biological mechanisms remain unclear. Long-term illness in patients with DM damages various organs in the body...
Detailed Description
Study design: This prospective interventional case study will be conducted on 60 eyes of 60 patients with resistant centrally involved diabetic macular edema following at least 3 doses of anti\_VEGF t...
Eligibility Criteria
Inclusion
- This study included resistant centrally involved diabetic macular edema (DME) cases
- \-
Exclusion
- Patients with a history of intraocular surgery
- coincident retinal pathology such as retinal vascular occlusion, CNV due to age-related macular degeneration, angioid streaks, trauma, and choroiditis were excluded from the study.
- patients who received other lines of treatment for DME, such as laser photocoagulation, intravitreal injection of steroids
- patients known to be glaucomatous or have an IOP ≥20 mmHg were also excluded.
- \-
Key Trial Info
Start Date :
October 19 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 19 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06879301
Start Date
October 19 2025
End Date
December 19 2025
Last Update
March 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
faculty of medicine, Tanta University
Tanta, Egypt, 1335